Search
Axsome Therapeutics Inc
AXSMAdd to Watchlist
250.500USD
-1.660-0.66%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
12.88BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Axsome Therapeutics Inc is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 185.00, with a high of 205.00 and a low of 148.00.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
273.850
Target Price
+9.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Axsome Therapeutics Inc
AXSM
21
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Axsome Therapeutics Inc's expected revenue for the next quarter?
Axsome Therapeutics Inc's expected revenue is 219.89M.
What is Axsome Therapeutics Inc's price target?
Analysts forecast that Axsome Therapeutics Inc's price target is USD 185.00, with the highest forecast at USD 205.00 and the lowest forecast at USD 148.00.
How have Axsome Therapeutics IncAXSM's recent earnings per share performed?
The market expectation was USD -1.26, while Axsome Therapeutics IncAXSM's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -0.88.
What is the analyst rating for Axsome Therapeutics Inc?
Based on the ratings of Axsome Therapeutics Inc's stock from 21 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
